AI Is Changing Pharma. Learn From Someone Who Knows Drug Development From the Inside.
Understanding how AI is reshaping pharma requires more than understanding the technology. It requires an understanding of drug development, clinical research, regulation, and the environments in which these technologies are actually being applied.
That perspective will be at the centre of our upcoming workshop, Proof, Not Promise: How AI Is Actually Changing Pharma, led by Dr. Tigran Uzunyan, Instructor at AAPS.
A medical doctor and research scientist, Dr. Uzunyan brings more than 18 years of experience across academia, the pharmaceutical industry, and clinical research. After earning his medical degree and specializing in clinical pharmacology, he completed his PhD in Pharmacology in 2008.
His experience spans the drug development lifecycle, including the design and conduct of early-phase studies such as bioequivalence, bioavailability, and first-in-human trials, as well as Phase II to IV clinical and observational studies. He has worked with drug development and regulatory requirements across multiple jurisdictions and has also managed medical cannabis development research projects in Canada.
That breadth of experience provides an important lens for examining AI in pharma today: not simply through what the technology promises, but through the realities of evidence, clinical application, risk, regulation, and compliance.
In this workshop, Dr. Uzunyan will explore:
- The Paradigm Shift: How Big Data and AI are changing pharma’s operating assumptions
- Discovery, Trials & Safety: Where AI has delivered meaningful results and where evidence remains limited
- Regulatory Frameworks: How FDA, EMA, and ICH expectations are evolving
- Context of Use: How to evaluate AI applications through a risk-based regulatory lens
- The Next 12–18 Months: Developments that could affect regulatory and compliance obligations
Learn from experience that spans medicine, research, clinical trials, and drug development.
Designed for Clinical Research, Regulatory Affairs, and Pharma professionals already familiar with AI basics, this session connects the technology with the real-world scientific and regulatory environment in which it must operate. |
